Sentinel* joints | All joints | |||||
Placebo (n=105) | Apremilast (n=203) | Difference (95% CI) | Placebo (n=105) | Apremilast (n=203) | Difference (95% CI) | |
cDAPSA REM/LDA, n (%) | 54 (51.8) | 143 (70.2) | 18.6% (7.0 to 30.2) p=0.0017 | 40 (38.0) | 122 (60.3) | 22.5% (10.7 to 34.3) p=0.0004† |
SJC≤1, n (%) | 72 (69.0) | 150 (74.0) | 5.1 (−5.8 to 16.0) p=0.3539 | 43 (41.5) | 117 (57.9) | 16.4 (4.7 to 28.0) p=0.0068† |
TJC≤1, n (%) | 47 (44.4) | 134 (66.2) | 22.1 (10.4 to 33.7) p=0.0003† | 17 (16.7) | 77 (38.0) | 21.4 (11.6 to 31.2) p=0.0002† |
PtGA VAS≤20, n (%) | – | – | – | 20 (19.1) | 62 (30.4) | 11.8% (1.7 to 22.0) p=0.0286† |
Patient pain VAS≤15, n (%) | – | – | – | 14 (13.1) | 60 (29.4) | 16.3% (6.9 to 25.8) p=0.0022† |
PsAID-12, LS mean (SE) change from baseline | – | – | – | −0.4 (0.2) | −1.5 (0.2) | −1.0 (−1.5 to −0.6) p<0.0001† |
PASDAS good/moderate response, n (%) | 45 (42.7) | 122 (59.9) | 17.7% (5.7 to 29.7) p=0.0043† | 42 (39.8) | 120 (59.3) | 20.0% (8.1 to 32.0) p=0.0014† |
FAS. The number of responders was rounded based on the value given by multiple imputations.
*Sentinel joints are defined as joints affected at baseline.
†Nominal p value.
cDAPSA, Clinical Disease Activity in Psoriatic Arthritis; CI, confidence interval; csDMARD, conventional synthetic disease-modifying antirheumatic drug; FAS, full analysis set; LDA, low disease activity; LS, least squares; MDA, minimal disease activity; PASDAS, PsA Disease Activity Score; PsAID-12, Psoriatic Arthritis Impact of Disease; PtGA, Patient Global Assessment of disease activity; REM, remission; SE, standard error; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.